pimonidazole has been researched along with Malignant Melanoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denny, WA; Hay, MP; Lee, HH; Roberts, PB; Wilson, WR | 1 |
| Gaustad, JV; Rofstad, EK; Simonsen, TG | 1 |
| Ellingsen, C; Galappathi, K; Mathiesen, B; Ovrebø, KM; Rofstad, EK | 1 |
| Kageyama, K; Kato, S; Kimura, M; Miwa, N; Tanaka, H | 1 |
| el Gamoussi, R; Guichard, M; Stratford, IJ | 1 |
| el Gamoussi, R; Guichard, M; Prade, M; Stratford, IJ; Threadgill, MD | 1 |
| Galappathi, K; Graff, BA; Mathiesen, B; Nilsen, K; Rasmussen, H; Rofstad, EK | 1 |
| Guichard, ME; Lespinasse, F; Taghian, A | 1 |
| Dische, S | 1 |
| Bennett, MH; Dische, S; Orchard, R; Stratford, MR; Wardman, P | 1 |
| Bleehen, NM; Newman, HF; Workman, P | 1 |
| Bennett, MH; Des Rochers, C; Dische, S; Dunphy, EP; Minchinton, AI; Saunders, MI; Stratford, MR; Wardman, P | 1 |
12 other study(ies) available for pimonidazole and Malignant Melanoma
| Article | Year |
|---|---|
Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cell Hypoxia; Cell Line; Chemical Phenomena; Chemistry, Physical; Cricetinae; Cricetulus; Heterocyclic Compounds; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Solubility; Structure-Activity Relationship; Water | 1995 |
Development of hypoxia in a preclinical model of tumor micrometastases.
Topics: Animals; Blood Flow Velocity; Cell Hypoxia; Female; Humans; Melanoma; Mice; Mice, Inbred A; Mice, Nude; Nitroimidazoles; Rhodamines; Xenograft Model Antitumor Assays | 2010 |
pO₂ fluctuation pattern and cycling hypoxia in human cervical carcinoma and melanoma xenografts.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Coloring Agents; Connective Tissue; Female; Humans; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Nitroimidazoles; Oxygen; Oxygen Consumption; Partial Pressure; Transplantation, Heterologous; Uterine Cervical Neoplasms | 2012 |
Enhanced radiosensitization by liposome-encapsulated pimonidazole for anticancer effects on human melanoma cells.
Topics: Cell Line; Cell Survival; Humans; Liposomes; Materials Testing; Melanoma; Nanocapsules; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents | 2012 |
Relationship between intracellular concentration and radiosensitizing effect of pimonidazole and etanidazole on two human melanoma cell lines.
Topics: Etanidazole; Humans; In Vitro Techniques; Melanoma; Nitroimidazoles; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1993 |
Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole.
Topics: Animals; Autoradiography; Cell Line; Etanidazole; Humans; Melanins; Melanoma; Mice; Mice, Nude; Neoplasms, Experimental; Nitroimidazoles; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1993 |
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Topics: Animals; Cell Hypoxia; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Melanoma; Mice; Mice, Inbred BALB C; Nitroimidazoles; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation | 2002 |
Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts.
Topics: Adenocarcinoma; Animals; Cell Survival; Drug Synergism; Etanidazole; Female; Humans; Melanoma; Mice; Mice, Nude; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Rectal Neoplasms | 1991 |
Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hypoxia; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitroimidazoles; Palliative Care; Radiation Tolerance; Radiation-Sensitizing Agents; Skin Neoplasms | 1987 |
The uptake of the radiosensitizing compound Ro 03-8799 (Pimonidazole) in human tumors.
Topics: Breast Neoplasms; Female; Humans; Melanoma; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Rectal Neoplasms; Uterine Cervical Neoplasms | 1989 |
A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.
Topics: Adenocarcinoma; Drug Combinations; Drug Evaluation; Etanidazole; Humans; Melanoma; Nitroimidazoles; Radiation-Sensitizing Agents | 1986 |
A comparison of the tumour concentrations obtainable with misonidazole and Ro 03-8799.
Topics: Adult; Aged; Animals; Carcinoma, Squamous Cell; Cricetinae; Cricetulus; Female; Humans; Male; Melanoma; Mice; Middle Aged; Misonidazole; Nitroimidazoles; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms | 1986 |